• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BIOLASE TO REPORT FIRST QUARTER 2023 RESULTS ON MAY 11, 2023

    5/4/23 4:05:00 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care
    Get the next $BIOL alert in real time by email

    LAKE FOREST, Calif., May 4, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that it will release first quarter 2023 financial and operating results on Thursday, May 11, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

    BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)

    To access the live call, dial 877-545-0523 (U.S.) or +1 973-528-0016 (International) and provide the following access code: 180082.

    A live and archived webcast of the conference call will be accessible on the BIOLASE Investor Relations Page. In addition, a phone replay will be available approximately two hours following the end of the call, and it will remain available for one week. To access the call replay, dial 877-481-4010 or +1 919-882-2331 (International) and enter replay passcode 48342.

    About BIOLASE

    BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 259 actively patented and 24 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2022, BIOLASE has sold over 45,500 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

    For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

    BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

    Contacts:

    EVC Group, Inc.

    Michael Polyviou/Todd Kehrli

    (732) 232-6914

    [email protected]; [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-to-report-first-quarter-2023-results-on-may-11-2023-301816574.html

    SOURCE BIOLASE, Inc.

    Get the next $BIOL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Colliers Securities resumed coverage on BIOLASE with a new price target

      Colliers Securities resumed coverage of BIOLASE with a rating of Buy and set a new price target of $1.15

      3/8/21 4:09:02 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • Maxim Group reiterated coverage on BIOLASE with a new price target

      Maxim Group reiterated coverage of BIOLASE with a rating of Buy and set a new price target of $2.00 from $1.00 previously

      1/26/21 4:24:15 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    SEC Filings

    See more
    • SEC Form 8-K filed by Biolase Inc.

      8-K - BIOLASE, INC (0000811240) (Filer)

      10/8/24 4:47:14 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • Biolase Inc. filed SEC Form 8-K: Bankruptcy or Receivership

      8-K - BIOLASE, INC (0000811240) (Filer)

      10/1/24 4:05:10 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Biolase Inc.

      8-K - BIOLASE, INC (0000811240) (Filer)

      9/6/24 4:05:08 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BIOLASE Voluntarily Initiates Chapter 11 Proceedings

      LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.The Company also announced today that it is pursuing a sale process under Section 363 of the Bankruptcy Code in conjunction with the filing. To this end, BIOL

      10/1/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

      LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

      8/8/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BIOL
    Leadership Updates

    Live Leadership Updates

    See more
    • Strateos Appoints Alexander K. Arrow as Chief Financial Officer and Expands Team

      Juliet M. Moritz appointed Vice President, Project Management Office Strateos, Inc., a pioneer in the development of remote access laboratories and lab automation software for life science research, today announced the appointment of Alexander K. Arrow, MD, CFA, as Chief Financial Officer. Dr. Arrow will join the Executive Leadership team and play a key role in leading the company's business and finance strategy focused on growth and new investments. The company has also named Juliet M. Moritz, MPH, Vice President, Project Management Office, reflecting the significant demand by large pharmaceutical companies and contract research organizations for deployment of Strateos Lodestar™ Software.

      2/8/23 8:00:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER

      Dr. Morrow brings extensive clinical, dental and DSO experience to help expand laser adoption globally LAKE FOREST, Calif., Oct. 13, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced the appointment of Russell Morrow, D.D.S. as Chief Dental Officer ("CDO"), effective November 1, 2022. Dr. Samuel Low, who has served as Chief Dental Officer since 2016, will be taking on a new role as Vice President, Clinical Strategic Alliances, where he will focus on building partnerships and growth with Dental Service Organizations (DSOs), universities and government institutions.

      10/13/22 6:30:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE Expands Core Capabilities As It Appoints Three New Board Members With Significant Dental Experience

      FOOTHILL RANCH, Calif., Aug. 16, 2021 /PRNewswire/ -- Demonstrating a deep commitment to expanding the core capabilities and diversity of its Board of Directors, BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced it has appointed three new board members to its Board of Directors (the "Board"), effective immediately. Drs. Kathleen T. O'Loughlin, Carol Gomez Summerhays, and Martha Somerman join a Board that has been instrumental in establishing and implementing the Company's business plan, which has demonstrated significant growth over the past several quarters.

      8/16/21 6:30:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Financials

    Live finance-specific insights

    See more
    • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

      LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

      8/8/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability

      Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and SuccessLAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024.First Quarter Financial HighlightsGenerated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialistsThird strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptionsGross margin was re

      5/13/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/23/24 4:05:29 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/21/24 4:39:54 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/14/24 4:06:57 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Yale Kenneth P.

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:10:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Somerman Martha J. Dds, Phd

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:08:49 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Roper Jess

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:07:19 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care